-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
CASI Pharmaceuticals, Inc (DE) quarterly/annual Earnings Per Share, Diluted history and growth rate from 2020 to 2022.
- CASI Pharmaceuticals, Inc (DE) Earnings Per Share, Diluted for the quarter ending December 31, 2022 was -2.01 USD/shares, a 48.9% decline year-over-year.
- CASI Pharmaceuticals, Inc (DE) Earnings Per Share, Diluted for the twelve months ending December 31, 2022 was -3.01 USD/shares, a 11.9% decline year-over-year.
- CASI Pharmaceuticals, Inc (DE) annual Earnings Per Share, Diluted for 2022 was -3.01 USD/shares, a 11.9% decline from 2021.
- CASI Pharmaceuticals, Inc (DE) annual Earnings Per Share, Diluted for 2021 was -2.69 USD/shares, a 38.4% increase from 2020.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)